Topical Betamethasone Research Articles

Steroid inhibition of oedema formation in the rat skin.

1. A model has been developed to compare the inhibitory effects of the topical steroid, betamethasone-17-valerate, to those of systemically administered betamethasone upon oedema responses induced by 5-hydroxytryptamine (5-HT), platelet activating factor (PAF) and zymosan-activated serum (ZAS) +/- prostaglandin E1 (PGE1), measured in the rat skin by use of 125I-labelled human serum albumin. 2. Systemic betamethasone had a selective, time- and dose-dependent inhibitory effect upon oedema treatment, with 1 mg kg-1 and a 3 h pretreatment having the greatest effect of the doses and times employed. 3. Topical betamethasone inhibited the oedema responses to all of the stimuli showing no apparent selectivity. 4. Topical betamethasone inhibits inflammatory stimuli in a different manner from systemic betamethasone. The broad spectrum of inhibition suggests that topical betamethasone acts by affecting a fundamental feature of the inflammatory response common to all of the stimuli.

Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay.

An in vivo technique has been developed which simultaneously compares a skin blanching bioassay with drug content in human stratum corneum following topical application of four 0.05% betamethasone dipropionate formulations. Bioavailability of drug from commercial cream and ointment formulations was assessed by quantification of drug content in tape-stripped stratum corneum and skin blanching in the treated skin site under occluded conditions. Tape-stripping removed stratum corneum to a varying degree between individuals but was consistent (35%) within an individual with all formulations, day to day. A correlation (r = 0.9935) between the amount of drug in the treated stratum corneum normalized for surface area and the corresponding skin blanching score was observed with four 0.05% betamethasone dipropionate formulations. Increasing the amount of drug in the tape-stripped stratum corneum correlated with an increased skin blanching score. Ointment formulations delivered more drug to the skin and produced greater blanching scores than the cream formulations. Topical corticosteroid content in the treated skin site can therefore be quantified and correlates well with the resulting pharmacodynamic activity.

Efficacy of Bimolane in the Malassezia ovalis Model of Psoriasis

Bimolane, an analog of razoxane has been used in China with comparable efficacy but less toxicity than razoxane in the treatment of psoriasis. In an attempt to characterize further its mode of action it was administered both systemically and topically in the Malassezia ovalis animal model of psoriasis. Intravenous methotrexate and topical 0.1% betamethasone valerate were also used as positive control treatments. The animal model of psoriasis was effectively treated by bimolane, both systemically and topically, and also by parenteral methotrexate and topical betamethasone valerate. The time course of bimolane's effect with this model was different from methotrexate's suggesting the possibility of a different mode of action. Because bimolane, like razoxane, is an ethylene diamino tetraacetate acid (EDTA) derivative, it is possible that its effects on this reaction relate to its chelating properties and that inhibition of complement activation is important to its mode of action.

Regression of scleromyxedema with topical betamethasone and dimethyl sulfoxide: a 30-month follow-up

Regression of scleromyxedema with topical betamethasone and dimethyl sulfoxide: a 30-month follow-up

Regression of Scleromyxedema With Topical Betamethasone and Dimethyl Sulfoxide: A 30-Month Follow-up

<h3>To the Editor.—</h3> Scleromyxedema is the generalized variant of papular mucinosis. It is commonly associated with a benign monoclonal immunoglobulin, and it may be associated with systemic manifestations.²Topical therapy is usually ineffective, and various systemic treatments have been tried. Dramatic responses have been reported with therapy with antimetabolites, but serious side effects and deaths have occurred; these events have led to the search for newer approaches. We report the regression of cutaneous signs with the combination therapy of topical betamethasone and dimethyl sulfoxide that was followed up over 30 months. <h3>Report of a Case.—</h3> A 66-year-old white man first observed gradual infiltration of the skin of his face, hands, and feet in December 1986. He presented with waxy infiltration of the hands, forearms, elbows, face, upper trunk, and thighs and lichenoid papules of the abdomen and buttocks. A biopsy specimen showed split and fragmented collagen bundles interspersed

Penicillamine‐Induced Pemphigus Erythematosus

Pemphigus erythematosus occurred in a patient with rheumatoid arthritis who was treated with D-penicillamine. The skin lesions appeared 4 months after the onset of D-penicillamine treatment and persisted 14 years after cessation of this drug. Topical betamethasone dipropionate applications resulted in complete regression of the cutaneous lesions.

Effects of widespread dermatitis and topical steroid therapy on thyroid function tests.

Five patients with extensive dermatitis and 5 normal subjects were treated with topical betamethasone valerate 0.1% (Betnovate, Glaxo) 19-34 g daily for 4 days. Thyroid functions tests were not affected by the treatment but some patients with widespread inflamed skin demonstrated altered serum thyroid hormone levels as a result of the euthyroid sick syndrome.

A Test of the Half‐side Comparative Design in the Clinical Evaluation of Topical Steroids, Using Diflucortolone and Betamethasone Creams

International Journal of Clinical PracticeVolume 39, Issue 10 p. 383-392 Clinical Study A Test of the Half-side Comparative Design in the Clinical Evaluation of Topical Steroids, Using Diflucortolone and Betamethasone Creams Correction(s) for this article Erratum Volume 39Issue 11-12International Journal of Clinical Practice pages: 448-448 First Published online: November 1, 1985 P. J. August MBBS, MRCP, P. J. August MBBS, MRCP The Skin Hospital, University of ManchesterSearch for more papers by this authorN. E. Platt, N. E. Platt Medical Department, Schering Chemicals Limited, West SussexSearch for more papers by this authorR. A. Wiseman PhD, MRCS, DObst RCOG, R. A. Wiseman PhD, MRCS, DObst RCOG Medical Department, Schering Chemicals Limited, West SussexSearch for more papers by this author P. J. August MBBS, MRCP, P. J. August MBBS, MRCP The Skin Hospital, University of ManchesterSearch for more papers by this authorN. E. Platt, N. E. Platt Medical Department, Schering Chemicals Limited, West SussexSearch for more papers by this authorR. A. Wiseman PhD, MRCS, DObst RCOG, R. A. Wiseman PhD, MRCS, DObst RCOG Medical Department, Schering Chemicals Limited, West SussexSearch for more papers by this author First published: 01 October 1985 https://doi.org/10.1111/j.1742-1241.1985.tb07865.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Volume39, Issue10October 1985Pages 383-392 RelatedInformation

Topical betamethasone 17-valerate is an anticorticosteroid in the rat. 1. Dermal atrophy.

In the albino rat, topical betamethasone 17-valerate acts as an anticorticosteroid. This steroid is inactive in a dermal atrophy assay over a dose range where betamethasone and hydrocortisone display atrophogenic activity. At appropriate concentrations betamethasone 17-valerate competitively inhibits the atrophogenic effects of both betamethasone and triamcinolone acetonide. Since betamethasone and betamethasone 17-valerate penetrate rat skin in vivo at essentially the same rate, it is concluded that the latter compound is relatively resistant to hydrolysis during penetration, and that it binds to rat corticosteroid receptor proteins in such a manner as to prevent expression of corticosteroid activity. Therefore, the rat cannot be used as a model species to predict activity in man for this compound.

Selective Photometric Determination of Betamethasone Benzoate and Other 21-Hydroxycorticosteroids

Condensation of the glyoxal obtained by cupric acetate oxidation of 21-hydroxycorticosteroids with acetous phenylhydrazine reagent affords a near UV chromophore. All of the tested corticosteroids, including triamcinolone acetonide, which gives low color yields in the Porter-Silber reaction and its Lewbart-Mattox modification, gave similar absorption maxima (362−370nm) and molar absorptivities (ε=17,000−20,500). Since corticosteroid 21-esters and oxidation products do not undergo the reaction, the assay method based on it is stability indicating for betamethasone benzoate and the other test compounds. Procedures are described for the assay of two topical betamethasone benzoate preparations and hydrocortisone and prednisolone tablets; recovery and precision data are given.

Corticosteroid Therapy for the Reduction of Postoperative Inflammation After Cataract Extraction

In an random, double-masked multicentric clinical trial, topical betamethasone phosphate 0.1% or placebo eyedrops were used five times daily for the first two weeks after uncomplicated intracapsular cataract extraction in 107 patients who had moderate to severe postoperative inflammation on the first postoperative day. Topical corticosteroid solution was significantly more effective than placebo in the reduction of postoperative ocular inflammation. There were no ocular complications of corticosteroid treatment.

The Influence Of Corticosteroids And Topical Indomethacin On Sunburn Erythema

The extent to which topical and intradermal corticosteroids and topical indomethacin suppress sunburn erythema was investigated in human volunteers. Both agents retarded the onset and decreased the magnitude of delayed erythema. Suppression by corticosteroids was not demonstrable with ultraviolet doses larger than 2 MEDs (minimal erythema dose). Below 2 MEDs, topical betamethasone valerate produced a dose-related suppression of erythema. Indomethacin was more effective and produced a measurable dose-dependent suppression against 3 and 6 MEDs. Despite significant inhibition of erythema, sunburn damage to epidermal cells was not altered by these drugs.

Betamethasone 17-Benzoate外用剤の貨幣状湿疹にたいする治療経験

Betamethasone 17-Benzoate外用剤の貨幣状湿疹にたいする治療経験

Letter: The treatment of cavernous haemangioma with topical betamethasone 17 valerate.

Journal Article THE TREATMENT OF CARVERNOUS HAEMANGIOMA WITH TOPICAL BETAMETHASONE 17 VALERATE Get access G. Weber G. Weber Skin Clinic City Hospital 85 Nurnberg 5 Germany Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 89, Issue 6, 1 December 1973, Pages 649–651, https://doi.org/10.1111/j.1365-2133.1973.tb07596.x Published: 01 December 1973

Double‐blind Clinical Comparisons of Topical Betamethasone Valerate and Betamethasone Benzoate in the Treatment of Steroid‐responsive Dermatoses

Double‐blind Clinical Comparisons of Topical Betamethasone Valerate and Betamethasone Benzoate in the Treatment of Steroid‐responsive Dermatoses

Nonsurgical Method of Treatment of Childhood Phimosis with the use of Topical Betamethasone

Background: Topical steroid application is an effective alternative to circumcision for the treatment of infant and childhood phimosis. Materials &amp; method: prospective study in 42 boys under 13 years of age, with non retractable foreskin with asymptomatic and past history of disease in grade 4 to 6 weeks treatment. the success was defined as full and free retraction, or easy retraction limited only by congenital adhesions to the glans. Results: Forty-two patients completed the treatment. Successful retraction was achieved in 14 (33.33%) at 4 weeks and 32(76.19%) after 6 weeks of application. No adverse systemic side effects were noted. Two patients had failed treatment and were enrolled for circumcision. Two patients refused further treatment. Six patients were lost in subsequent to follow-up. Conclusion: Betamethasone 0.10% ointment is an effective alternative, non surgical method of the treatment for the childhood phimosis. Keywords: Chilhood phimosis; betamethasone DOI: 10.3126/hren.v8i3.4211Health Renaissance, September-December 2010; Vol 8 (No.3);176-180